抗VEGF药物联合全视网膜光凝术治疗增生高危期糖尿病视网膜病变疗效探讨  

Intravitreal Anti-VEGF Combined With Panretinal Photocoagulation in the Treatment of High-risk Proliferative Diabetic Retinopathy

作　　者：刘历东[1] 

机构地区：[1]内蒙古医科大学附属医院眼科,内蒙古呼和浩特010050

出　　处：《中国继续医学教育》2016年第25期83-84,共2页China Continuing Medical Education

摘　　要：目的 探讨应用抗VEGF药物玻璃体内注射联合全视网膜光凝治疗增生高危期糖尿病视网膜病变的治疗效果。方法 选取我院2015年1月~2016年5月收治的增生高危期糖尿病视网膜病变患者20例（22眼）,注射后7~10 d或者玻璃体清晰时开始进行全视网膜光凝治疗,对全部患者的治疗效果进行回顾性分析。结果 本组患者经治疗后视网膜渗漏明显减轻,玻璃体积血在注药1周即有部分吸收,玻璃体积血完全吸收平均（8.5±2.3）周。视力提高大于3行的14只眼,提高1~3行的5只眼,视力无明显改善的3只眼,总有效率86.36%。视网膜新生血管消退时间平均（10.6±3.5）周。本组患者平均注射药物次数（1.5±0.5）次,全部患者均未出现与注药相关的眼部并发症。结论 抗VEGF药物联合全视网膜光凝术治疗增生高危期糖尿病视网膜病变具有较高疗效和安全性,但还需要更长期的观察。Objective To discuss the efifcacy of intravitreal Ranibizumab injection combined with panretinal laser photocoagulation in patients with high-risk PDR.Methods From January 2015 to May 2016, study was conducted in 20 patients （22 eyes） with high risk PDR, who were treated with intravitreal Ranibizumab （0.5mg） followed by PRP when the peripheral vitreous became clear 7~10 days after injection. Retrospective analysis was made.ResultsAll patients had odvious reduction in angiographic leakage and involution of retinal neovascularization （NV）. The vitreous hemorrhage showed a partial resolution as early as 1 week, clear up time was （8.5±2.3） weeks. The effective percentage was 86.36%. NVD and NVE regression was （10.6±3.5） weeks. Patients received an average of （1.5±0.5） injections. No ocular adverse events were observed following injections.Conclusion Anti-VEGF drugs combined with total retinal photocoagulation for the treatment of high risk diabetic retinopathy with high efifcacy and safety. But more long-term observations are needed.

关 键 词：抗VEGF 全视网膜光凝 增生性糖尿病视网膜病变 

分 类 号：R587.2[医药卫生—内分泌]